FI3864009T3 - TYK2-kinaasi-inhibiittoreita - Google Patents
TYK2-kinaasi-inhibiittoreita Download PDFInfo
- Publication number
- FI3864009T3 FI3864009T3 FIEP19794095.0T FI19794095T FI3864009T3 FI 3864009 T3 FI3864009 T3 FI 3864009T3 FI 19794095 T FI19794095 T FI 19794095T FI 3864009 T3 FI3864009 T3 FI 3864009T3
- Authority
- FI
- Finland
- Prior art keywords
- compound
- compound according
- hydrogen
- formula
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1816369.1A GB201816369D0 (en) | 2018-10-08 | 2018-10-08 | Pharmaceutical compounds |
| PCT/EP2019/077118 WO2020074461A1 (en) | 2018-10-08 | 2019-10-07 | Tyk2 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3864009T3 true FI3864009T3 (fi) | 2025-03-24 |
Family
ID=64397425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19794095.0T FI3864009T3 (fi) | 2018-10-08 | 2019-10-07 | TYK2-kinaasi-inhibiittoreita |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12187716B2 (https=) |
| EP (1) | EP3864009B1 (https=) |
| JP (1) | JP7383030B2 (https=) |
| KR (1) | KR102844196B1 (https=) |
| CN (1) | CN113056456B (https=) |
| AU (1) | AU2019359320B2 (https=) |
| BR (1) | BR112021006424A2 (https=) |
| CA (1) | CA3111049A1 (https=) |
| DK (1) | DK3864009T3 (https=) |
| ES (1) | ES3021420T3 (https=) |
| FI (1) | FI3864009T3 (https=) |
| GB (1) | GB201816369D0 (https=) |
| IL (1) | IL281599B2 (https=) |
| MX (1) | MX2021003929A (https=) |
| PL (1) | PL3864009T3 (https=) |
| PT (1) | PT3864009T (https=) |
| SG (1) | SG11202102490TA (https=) |
| WO (1) | WO2020074461A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202005114D0 (en) * | 2020-04-07 | 2020-05-20 | Sareum Ltd | Crystalline Forms of a Pharmaceutical Compound |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE794096A (fr) | 1972-08-07 | 1973-05-16 | Lepetit Spa | Oxazoles 2,4,5-trisubstitues et leur preparation |
| GB1497536A (en) | 1973-12-17 | 1978-01-12 | Lilly Industries Ltd | 2-acylaminooxazoles methods for their preparation and their use |
| DE19653355A1 (de) | 1996-12-20 | 1998-06-25 | Dresden Arzneimittel | Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung |
| GB0003154D0 (en) | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
| IL153246A0 (en) | 2000-06-28 | 2003-07-06 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
| DE60128731T2 (de) | 2000-10-30 | 2008-02-07 | Janssen Pharmaceutica N.V. | Tripeptidylpeptidase-hemmer |
| US7361665B2 (en) | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| EP1684750B1 (en) | 2003-10-23 | 2010-04-28 | AB Science | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors |
| GB0504753D0 (en) | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| JP5222561B2 (ja) | 2005-10-07 | 2013-06-26 | キッセイ薬品工業株式会社 | 含窒素芳香族複素環化合物およびそれを含有する医薬組成物 |
| ES2352320T3 (es) | 2006-05-12 | 2011-02-17 | Ab Science | Nuevo procedimiento para la síntesis de compuestos de 2-aminoxazol. |
| WO2008024980A2 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Pyrrole, thiophene, furan, imidazole, oxazole, and thiazole derivatives |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| JP5478488B2 (ja) | 2007-06-20 | 2014-04-23 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｊａｎｕｓキナーゼの阻害剤 |
| EP2278969B1 (en) | 2008-04-21 | 2013-02-13 | Merck Sharp & Dohme Corp. | Inhibitors of Janus kinases |
| EP2299816B1 (en) | 2008-06-18 | 2013-11-13 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| US8420695B2 (en) | 2008-07-09 | 2013-04-16 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| EP2166006A1 (en) | 2008-09-18 | 2010-03-24 | Dompe' S.P.A. | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
| GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
| US20130096104A1 (en) | 2010-03-17 | 2013-04-18 | Genentech, Inc. | Imidazopyridine compounds, compositions and methods of use |
| EP2588105A1 (en) | 2010-07-01 | 2013-05-08 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
| WO2012021611A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| CN103987713A (zh) | 2011-10-12 | 2014-08-13 | 阵列生物制药公司 | 5,7-取代的咪唑并[1,2-c]嘧啶 |
| GB201202027D0 (en) | 2012-02-06 | 2012-03-21 | Sareum Ltd | Pharmaceutical compounds |
| EP3040336B1 (en) * | 2012-03-02 | 2020-04-08 | Sareum Limited | Compounds for use in treating tyk2 kinase mediated conditions |
| KR101202026B1 (ko) | 2012-07-03 | 2012-11-16 | 민호현 | 황토 석부작 제조 방법 |
| LT3495358T (lt) | 2012-11-08 | 2022-05-25 | Bristol-Myers Squibb Company | Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai |
| MX369974B (es) | 2013-09-03 | 2019-11-27 | Sareum Ltd | Compuestos farmaceuticos. |
| JP6310767B2 (ja) | 2014-05-13 | 2018-04-11 | 日本電子株式会社 | 自動分析装置及びノズル洗浄方法 |
| NO2721710T3 (https=) | 2014-08-21 | 2018-03-31 | ||
| GB201617871D0 (en) | 2016-10-21 | 2016-12-07 | Sareum Limited | Pharmaceutical compounds |
| GB202005114D0 (en) | 2020-04-07 | 2020-05-20 | Sareum Ltd | Crystalline Forms of a Pharmaceutical Compound |
-
2018
- 2018-10-08 GB GBGB1816369.1A patent/GB201816369D0/en not_active Ceased
-
2019
- 2019-10-07 US US17/283,151 patent/US12187716B2/en active Active
- 2019-10-07 PL PL19794095.0T patent/PL3864009T3/pl unknown
- 2019-10-07 CA CA3111049A patent/CA3111049A1/en active Pending
- 2019-10-07 MX MX2021003929A patent/MX2021003929A/es unknown
- 2019-10-07 KR KR1020217013504A patent/KR102844196B1/ko active Active
- 2019-10-07 EP EP19794095.0A patent/EP3864009B1/en active Active
- 2019-10-07 CN CN201980066166.4A patent/CN113056456B/zh active Active
- 2019-10-07 IL IL281599A patent/IL281599B2/en unknown
- 2019-10-07 WO PCT/EP2019/077118 patent/WO2020074461A1/en not_active Ceased
- 2019-10-07 JP JP2021543577A patent/JP7383030B2/ja active Active
- 2019-10-07 BR BR112021006424A patent/BR112021006424A2/pt unknown
- 2019-10-07 ES ES19794095T patent/ES3021420T3/es active Active
- 2019-10-07 SG SG11202102490TA patent/SG11202102490TA/en unknown
- 2019-10-07 AU AU2019359320A patent/AU2019359320B2/en active Active
- 2019-10-07 FI FIEP19794095.0T patent/FI3864009T3/fi active
- 2019-10-07 PT PT197940950T patent/PT3864009T/pt unknown
- 2019-10-07 DK DK19794095.0T patent/DK3864009T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7383030B2 (ja) | 2023-11-17 |
| CA3111049A1 (en) | 2020-04-16 |
| CN113056456A (zh) | 2021-06-29 |
| EP3864009A1 (en) | 2021-08-18 |
| MX2021003929A (es) | 2021-06-04 |
| KR20210076036A (ko) | 2021-06-23 |
| IL281599A (en) | 2021-05-31 |
| AU2019359320B2 (en) | 2024-04-04 |
| DK3864009T3 (da) | 2025-03-17 |
| JP2022514799A (ja) | 2022-02-15 |
| IL281599B2 (en) | 2024-10-01 |
| IL281599B1 (en) | 2024-06-01 |
| PT3864009T (pt) | 2025-04-23 |
| ES3021420T3 (en) | 2025-05-26 |
| US12187716B2 (en) | 2025-01-07 |
| EP3864009B1 (en) | 2025-02-19 |
| GB201816369D0 (en) | 2018-11-28 |
| WO2020074461A1 (en) | 2020-04-16 |
| CN113056456B (zh) | 2023-06-13 |
| PL3864009T3 (pl) | 2025-04-22 |
| BR112021006424A2 (pt) | 2021-07-06 |
| KR102844196B1 (ko) | 2025-08-07 |
| US20210387981A1 (en) | 2021-12-16 |
| AU2019359320A1 (en) | 2021-03-18 |
| SG11202102490TA (en) | 2021-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| FI3788047T3 (fi) | Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi | |
| MX2021009199A (es) | Conjugado de farmaco de dos ligandos y uso del mismo. | |
| SA519402217B1 (ar) | مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون | |
| MY201603A (en) | Combination of dextromethorphan and bupropion for treating depression | |
| JP2018513107A5 (https=) | ||
| EA202092343A1 (ru) | Лечение гнойного гидраденита с использованием ингибиторов jak | |
| MY196599A (en) | Pharmaceutical compositons comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
| CN110036005A (zh) | 酰胺衍生物及其在药物中的应用 | |
| FI3452039T3 (fi) | Hiustenlähtöhäiriöiden hoito deuteroiduilla JAK-estäjillä | |
| MX2023001468A (es) | Tratamiento de cancer de prostata. | |
| GEP20257716B (en) | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors | |
| MX2009010450A (es) | El uso de inhibidores de la fosfodiesterasa 7 para el tratamiento transtornos del movimiento. | |
| FI3840753T3 (fi) | Migalastaatti käytettäväksi fabryn taudin hoitomenetelmissä potilailla joilla on gla-geenin mutaatio | |
| PH12021551541A1 (en) | Compositions and methods for treating neurodegenerative disorders | |
| FI3864009T3 (fi) | TYK2-kinaasi-inhibiittoreita | |
| RU2019125177A (ru) | Новые производные амино-имидазопиридина в качестве ингибиторов янус-киназы и их фармацевтическое применение | |
| RU2019100037A (ru) | Способ лечения рассеянного склероза с использованием ингибитора lsd1 | |
| JOP20210019A1 (ar) | شكل جرعة صيدلانية تعطى عن طريق الفم ذات اطلاق مُعدّل | |
| EA201592058A1 (ru) | Применение ландиолола гидрохлорида в длительном лечении тахиаритмии | |
| GB2590189A9 (en) | Lycorine derivatives, pharmaceutical composite thereof and usage therefor | |
| JP2020504154A5 (https=) | ||
| JOP20240022A1 (ar) | مركبات وتركيبات لعلاج حالات مرتبطة بنشاط sting | |
| MX2023003783A (es) | Formulaciones farmaceuticas para tratar enfermedades mediadas por kdm1a. | |
| MX2026000979A (es) | Una forma farmaceutica solida de dosificacion bucodispersable de safinamida |